Date published: 2026-8-27

1-800-457-3801

SCBT Portrait Logo
Seach Input

TIP30 CRISPR/Cas9 KO Plasmid (h): sc-406742

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • TIP30 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TIP30 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TIP30 Antibody (F-10): sc-515728
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    TIP30 CRISPR/Cas9 KO Plasmid (h)

    sc-406742
    20 µg
    $397.00

    Overview

    HTATIP2 encodes TIP30 (also known as CC3), a cytoplasmic and nuclear protein implicated in regulation of transcriptional programs and cellular homeostasis. TIP30 has been linked to control of apoptosis, modulation of nucleocytoplasmic transport, and regulation of endocytic trafficking pathways that influence receptor turnover and growth factor signaling. Altered HTATIP2/TIP30 expression has been reported in multiple tumor contexts and is studied for its association with cell proliferation, invasion, and metastatic phenotypes. These properties make TIP30 a useful target for dissecting signaling networks that couple stress responses, trafficking, and gene regulation in human cells.

    TIP30 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the HTATIP2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the HTATIP2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the HTATIP2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TIP30 protein expression.

    This CRISPR knockout system enables efficient generation of HTATIP2-deficient cell models for investigation of TIP30 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting HTATIP2 exon(s) critical for TIP30 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple HTATIP2 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by TIP30 CRISPR/Cas9 KO Plasmid (h) and TIP30 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the HTATIP2 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by TIP30 HDR Plasmid (h) and TIP30 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by HTATIP2 homology arms to support homology-directed repair at defined HTATIP2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.